Vaccines have been established as a cost-effective way to reduce the morbidity associated with herpes simplex virus (HSV) types 1 and 2, especially the former. The prevalence of genital herpes caused by HSV-1 in worldwide populations has been a serious concern on the global health care systems. Strides made in the research and development of therapeutic and prophylactic vaccines to prevent the recurrence of infections have been vital in advancing the evolution of the HSV vaccines market. Further, a growing array of vaccines in early phase clinical trials, and the advent of numerous novel approaches put on trials, are bolstering new clinical avenues in the market.
Get Sample Copy of this Report @
The HSV vaccines market is witnessing growing interest of vaccine manufacturers on new approaches. In this regard, varicella zoster virus (VZV) vaccines have attracted intense research interest, in great part due to the fact that VZV and HSV share the same alphaherpesvirus subfamily. Continuous advances made in pre-clinical approaches to HSV vaccine development are opening new prospects in the market.
Efforts to Contain Spread of HIV to Propel Investments in HSV Vaccines Market
Developed nations have witnessed numerous seroprevalence studies to understand the pathogenesis of HSV-1 and HSV-2. For instance, HSV-2 is primarily considered as a sexually transmitted disease while the other type is linked with aggravating the prevalence of clinical genital herpes infections. More importantly, genital HSV infection is associated with the risk of HIV infection. Thus, over the past few years, countries around the world are expending efforts and energy in developing HSV vaccines to contain the spread of HIV. This trend will catalyze investments in the HSV vaccines market.
Distinct Advantages of Live Attenuated Vaccines over Other Types Generate Research Interest
Key approaches attracting interest of healthcare systems are purified peptides, inactivated, live attenuated, recombinant glycoprotein subunits, replication competent, and replication defective whole virus. The advent of DNA-based vaccines and continuous research to unlock their potential generate lucrative prospects in the HSV vaccines market. However, their vectors are proving to be inadequate since the vaccine approach needs multiple vaccinations to generate significant protective immune responses.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6151
In the coming years, live attenuated vaccines will gather traction in HSV vaccine market. The unique advantages over inactivated and subunit vaccines make them popular. These vaccines cater to a vast repertoire of cross-protective antigens and will be crucial in advancing the strides in the market.